Dynacirc

(Isradipine)

Phase 3Small molecule

GGlaxo Dba Glaxosmithkline

Dynacirc is one of 121 small molecule programs targeting Schizoaffective Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

120

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Schizoaffective DisorderActive, not recruiting

Parkinson DiseaseActive, not recruiting

Smoking CessationActive, not recruiting

Schizoaffective DisorderPreclinical

Active, not recruiting

Parkinson DiseasePhase 3

Active, not recruiting

Smoking CessationPhase 1

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Vesicare

Astellas

Phase 3

1 2

Byetta

Mirapex

3 4

Allegra

CChattem

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

1 6

Wakix

HHarmony Biosciences Management, Inc.

Phase 3

—7

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 3

—8

Aquasol E

NNational Eye Institute (NEI)

Xifaxan

Levodopa/carbidopa

Orion Corporation, Orion Pharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parkinson disease1 trial

Efficacy of Isradipine in Early Parkinson Disease

Completed·UUniversity of Rochester·Phase 3·NCT02168842·336 enrolled

Schizoaffective Disorder1 trial

Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

Completed·IIcahn School of Medicine at Mount Sinai·N/A·NCT01658150·11 enrolled

Buprenorphine1 trial

Improving Buprenorphine Detoxification Outcomes With Isradipine

Completed·UUniversity of Arkansas·Phase 1/2·NCT01895270·28 enrolled

Bipolar Depression1 trial

Adjunctive Isradipine for the Treatment of Bipolar Depression

Terminated·MMassachusetts General Hospital·Phase 2·NCT01784666·2 enrolled

MPA1 trial

Impact of Persistent Conductances on Motor Unit Firing in SCI

Unknown status·SShirley Ryan AbilityLab·N/A·NCT02136823·50 enrolled

2 more indications

Methadone1 trial

Drug Discrimination in Methadone-Maintained Humans Study 1

Completed·UUniversity of Arkansas·Phase 1·NCT00593463·40 enrolled

Smoking Cessation1 trial

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

Completed·UUniversity of Texas at Austin·Phase 1·NCT03083353·78 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 20, 1990

DYNACIRC

NDA NDA019546

Jun 1, 1994

DYNACIRC CR

NDA NDA020336

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Isradipine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isradipine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isradipine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020336). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGlaxo Dba Glaxosmithkline

Dynacirc

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Parkinson disease1 trial

Schizoaffective Disorder1 trial

Buprenorphine1 trial

Bipolar Depression1 trial

MPA1 trial

Methadone1 trial

Smoking Cessation1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News